0.00
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Radiopharm Theranostics
Its shares trade on ASX under the ticker RAD.AX. It has been listed since 25 November 2021. In the fiscal year to 30 June 2026, it reported revenue of A$2.8m and a net loss of A$55.1m. At that date it held total assets of A$60.1m and shareholders' equity of A$24.7m.
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The firm has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The firm's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Nov 2021
- Website
- radiopharmtheranostics.com ↗
Leadership
Pay as last reported
- Mr. Paul HopperExecutive Chairman of the Board, since 2021A$478,845
- Mr. Riccardo CanevariChief Executive Officer, Managing DirectorA$2.7m
- Mr. Phillip HainsChief Financial Officer, Executive Officer, Company SecretaryA$27,708
- Dr. Thomas TulipChief Business OfficerA$579,194
- Dr. Dimitris VoliotisChief Medical Officer
- Dr. Leila AllandNon-Executive Independent DirectorA$165,414
- Mr. Noel DonnellyNon-Executive Independent Director
- Ms. Hester LarkinNon-Executive Independent DirectorA$94,323
- Mr. Ian TurnerNon-Executive Independent DirectorA$476,518
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Radiopharm Theranostics Ltd. focuses on six platform technologies in cancer diagnostics and therapy.
- The company has a clinical program with one Phase II and three Phase I trials for solid tumor cancers.
- Nano-mAbs uses genetic engineered camelid antibodies for targeted radiopharmaceutical therapy.
Weaknesses
- The company operates in pre-clinical and clinical stages without commercialized products yet.
- Radiopharm Theranostics Ltd. has no revenue from product sales as a pre-clinical company.
- The firm's pipeline includes only six platform technologies without specific market validation.
Opportunities
- The firm's technologies target high unmet medical needs in cancer treatment areas.
- Phase II and Phase I trials in breast, kidney, and brain cancers offer potential market entry points.
- Pivalate and Nano-mAbs could expand into new diagnostic and therapeutic applications.
Threats
- The company faces competition from established biotechnology firms in the Health Care sector.
- Regulatory approval delays could impact the timeline for clinical trials and product launches.
- Market acceptance of new radiopharmaceuticals may be slow due to high costs and complexity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.